Influence of mofebutazone in comparison to phenylbutazone on the adenosine triphosphate level of polymorphonuclear cells and their migration.
Two pyrazolon derivatives--mofebutazone ( CAS 2210-63-1) and phenylbutazone ( CAS 50-33-9)--were compared as to their effects on the adenosine triphosphate (ATP) level of polymorphonuclear cells (PMNs) and their response to the migration of these cells. In the range of 10(-8) to 10(-3) mol/l neither mofebutazone nor phenylbutazone significantly changed the ATP level of PMNs. Compared to the untreated PMNs only phenylbutazone reduced the migration of PMNs significantly (chemotactic index (CI) 0.46) at a concentration of 10(-3) mol/l. On the other hand with mofebutazone no statistically significant abnormality on PMN migration was found. Direct statistical comparisons of the migration between specific concentrations of the two pharmaceuticals did not indicate a different migration behavior even at 10(-3) mol/l. These results show that in contrast to the chemical and pharmacological differences of mofebutazone and phenylbutazone their effect on the ATP level and the migration of PMNs is comparable.[1]References
- Influence of mofebutazone in comparison to phenylbutazone on the adenosine triphosphate level of polymorphonuclear cells and their migration. Partsch, G. Arzneimittel-Forschung. (1992) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
